170 related articles for article (PubMed ID: 38566191)
1. EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia.
Hou Z; Ren Y; Zhang X; Huang D; Yan F; Sun W; Zhang W; Zhang Q; Fu X; Lang Z; Chu C; Zou B; Gao B; Jin B; Kang Z; Liu Q; Yan J
Cell Commun Signal; 2024 Apr; 22(1):211. PubMed ID: 38566191
[TBL] [Abstract][Full Text] [Related]
2. EP300-ZNF384 fusion gene product up-regulates GATA3 gene expression and induces hematopoietic stem cell gene expression signature in B-cell precursor acute lymphoblastic leukemia cells.
Yaguchi A; Ishibashi T; Terada K; Ueno-Yokohata H; Saito Y; Fujimura J; Shimizu T; Ohki K; Manabe A; Kiyokawa N
Int J Hematol; 2017 Aug; 106(2):269-281. PubMed ID: 28378055
[TBL] [Abstract][Full Text] [Related]
3. Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing.
Jing Y; Li YF; Wan H; Liu DH
Ann Hematol; 2020 Nov; 99(11):2611-2617. PubMed ID: 32980888
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of Clinical Characteristics of Acute B Lymphoblastic Leukemia with EP300-ZNF384 Fusion Gene Positive].
Yao ZL; Li YF; Li M; Li Y; Li WJ; Li HH; Liu YY; Lin SH; Li FW; Zhang J; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):24-28. PubMed ID: 32027248
[TBL] [Abstract][Full Text] [Related]
5. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
Qian M; Zhang H; Kham SK; Liu S; Jiang C; Zhao X; Lu Y; Goodings C; Lin TN; Zhang R; Moriyama T; Yin Z; Li Z; Quah TC; Ariffin H; Tan AM; Shen S; Bhojwani D; Hu S; Chen S; Zheng H; Pui CH; Yeoh AE; Yang JJ
Genome Res; 2017 Feb; 27(2):185-195. PubMed ID: 27903646
[TBL] [Abstract][Full Text] [Related]
6. Detection of a Cryptic EP300/ZNF384 Gene Fusion by Chromosomal Microarray and Next-Generation Sequencing Studies in a Pediatric Patient with B-Lymphoblastic Leukemia.
Berg HE; Blackburn PR; Smadbeck JB; Swanson KE; Rice CS; Webley MR; Johnson SH; Vasmatzis G; Xu X; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Boston CH; Sutton LM; Peterson JF
Lab Med; 2021 May; 52(3):297-302. PubMed ID: 33145596
[TBL] [Abstract][Full Text] [Related]
7. Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression.
McClure BJ; Heatley SL; Kok CH; Sadras T; An J; Hughes TP; Lock RB; Yeung D; Sutton R; White DL
Br J Cancer; 2018 Apr; 118(7):1000-1004. PubMed ID: 29531323
[TBL] [Abstract][Full Text] [Related]
8. ZNF384-fusion proteins have high affinity for the transcriptional coactivator EP300 and aberrant transcriptional activities.
Yamamoto H; Hayakawa F; Yasuda T; Odaira K; Minamikawa Y; Tange N; Hirano D; Kojima Y; Morishita T; Tsuzuki S; Naoe T; Kiyoi H
FEBS Lett; 2019 Aug; 593(16):2151-2161. PubMed ID: 31234226
[TBL] [Abstract][Full Text] [Related]
9. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.
Hirabayashi S; Ohki K; Nakabayashi K; Ichikawa H; Momozawa Y; Okamura K; Yaguchi A; Terada K; Saito Y; Yoshimi A; Ogata-Kawata H; Sakamoto H; Kato M; Fujimura J; Hino M; Kinoshita A; Kakuda H; Kurosawa H; Kato K; Kajiwara R; Moriwaki K; Morimoto T; Nakamura K; Noguchi Y; Osumi T; Sakashita K; Takita J; Yuza Y; Matsuda K; Yoshida T; Matsumoto K; Hata K; Kubo M; Matsubara Y; Fukushima T; Koh K; Manabe A; Ohara A; Kiyokawa N;
Haematologica; 2017 Jan; 102(1):118-129. PubMed ID: 27634205
[TBL] [Abstract][Full Text] [Related]
10. Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B/ZNF384 gene fusion.
Shago M; Abla O; Hitzler J; Weitzman S; Abdelhaleem M
Pediatr Blood Cancer; 2016 Nov; 63(11):1915-21. PubMed ID: 27392123
[TBL] [Abstract][Full Text] [Related]
11. Zinc finger protein 384 (
Sudutan T; Erbilgin Y; Hatirnaz Ng O; Karaman S; Karakas Z; Kucukcankurt F; Celkan T; Timur C; Ozdemir GN; Hacısalihoglu S; Gelen SA; Sayitoğlu M
Leuk Lymphoma; 2022 Dec; 63(12):2931-2939. PubMed ID: 35921545
[TBL] [Abstract][Full Text] [Related]
12. Establishment and genetic characterization of a novel mixed-phenotype acute leukemia cell line with EP300-ZNF384 fusion.
Ping N; Qiu H; Wang Q; Dai H; Ruan C; Ehrentraut S; Drexler HG; MacLeod RA; Chen S
J Hematol Oncol; 2015 Aug; 8():100. PubMed ID: 26293203
[TBL] [Abstract][Full Text] [Related]
13. ZNF384-Related Fusion Genes in Acute Lymphoblastic Leukemia.
Zhu L; Bai W; Cheng Q; Fang J
Cancer Control; 2023; 30():10732748231182787. PubMed ID: 37306722
[TBL] [Abstract][Full Text] [Related]
14. A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia.
Gocho Y; Kiyokawa N; Ichikawa H; Nakabayashi K; Osumi T; Ishibashi T; Ueno H; Terada K; Oboki K; Sakamoto H; Shioda Y; Imai M; Noguchi Y; Arakawa Y; Kojima Y; Toyama D; Hata K; Yoshida T; Matsumoto K; Kato M; Fukushima T; Koh K; Manabe A; Ohara A;
Leukemia; 2015 Dec; 29(12):2445-8. PubMed ID: 25943178
[No Abstract] [Full Text] [Related]
15. Immunophenotypic characteristics of ZNF384 rearrangement compared with BCR-ABL1, KMT2A rearrangement, and other adult B-cell precursor acute lymphoblastic leukemia.
Wang YZ; Qin YZ; Chang Y; Yuan XY; Chen WM; He LL; Hao L; Shi WH; Jiang Q; Jiang H; Huang XJ; Liu YR
Cytometry B Clin Cytom; 2022 Sep; 102(5):360-369. PubMed ID: 35735203
[TBL] [Abstract][Full Text] [Related]
16. Systematic application of fluorescence in situ hybridization and immunophenotype profile for the identification of ZNF384 gene rearrangements in B cell acute lymphoblastic leukemia.
Janet NB; Kulkarni U; Arun AK; Bensega B; Devasia AJ; Korula A; Abraham A; George B; Mathews V; Balasubramanian P
Int J Lab Hematol; 2021 Aug; 43(4):658-663. PubMed ID: 33988307
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia.
Zhao X; Wang P; Diedrich JD; Smart B; Reyes N; Yoshimura S; Zhang J; Yang W; Barnett K; Xu B; Li Z; Huang X; Yu J; Crews K; Yeoh AEJ; Konopleva M; Wei CL; Pui CH; Savic D; Yang JJ
Nat Commun; 2022 Sep; 13(1):5401. PubMed ID: 36104354
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and outcomes of childhood B-ALL with ZNF384 and MEF2D rearrangements].
Hirabayashi S; Manabe A; Ohki K; Kiyokawa N
Rinsho Ketsueki; 2023; 64(7):633-638. PubMed ID: 37544723
[TBL] [Abstract][Full Text] [Related]
19. ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia.
Shi ZY; Wang X; Chen WM; Li LD; Hao Y; Li JY; Sun K; Zhao XS; Jiang H; Jiang Q; Huang XJ; Qin YZ
Hematol Oncol; 2024 Jan; 42(1):e3251. PubMed ID: 38287528
[TBL] [Abstract][Full Text] [Related]
20. MRD-Negative Remission Induced in EP300-ZNF384 Positive B-ALL Patients by Tandem CD19/CD22 CAR T-Cell Therapy Bridging to Allogeneic Stem Cell Transplantation.
Zhang XY; Dai HP; Zhang L; Liu SN; Dai Y; Wu DP; Tang XW
Onco Targets Ther; 2021; 14():5197-5204. PubMed ID: 34744437
[No Abstract] [Full Text] [Related]
[Next] [New Search]
